Emyria (ASX:EMD) is pleased to announce a second Emyria psychiatrist has been granted “Authorised Prescriber” (AP) status by the Therapeutic Goods Administration (TGA).
Notably, this is the first AP approval for MDMA-assisted therapy granted to a female psychiatry specialist in Australia. With the female incidence of PTSD almost twice that of males, Emyria can support a personalised approach to care and research.
The authorisation allows the prescribing of MDMA according to an ethics committee endorsed care model developed by Emyria and within the strict regulatory framework established by the TGA for the treatment of Post-Traumatic Stress Disorder (PTSD) and expands Emyria’s capacity for care and research.
Emyria CEO and MD, Dr. Michael Winlo, commented:
“Our second authorisation demonstrates Emyria’s commitment and ability to increase our service capacity to better evaluate emerging treatments for mental health within the strict regulatory frameworks established by the TGA.
“Our initial focus is on evaluating MDMA-assisted therapy for PTSD. With the female incidence of PTSD almost twice that of males, we are pleased to support an approach that acknowledges and addresses the specific needs of women suffering from PTSD by supporting the first approved female Authorised Prescriber for MDMA-AT.”
Click here to read the ASX release.
Disclaimer:
All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. These effects of psilocybin and MDMA are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision.